id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-N-4225-0133,FDA,FDA-2023-N-4225,Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products; Withdrawal,Proposed Rule,Withdrawal,2025-11-28T05:00:00Z,2025,11,2025-11-28T05:00:00Z,,2025-11-28T19:47:58Z,2025-21407,0,0,09000064b90a1ed0
FDA-2023-N-4225-0099,FDA,FDA-2023-N-4225,Request for Extension from U.S. Chamber of Commerce,Other,Request for Extension,2025-03-21T04:00:00Z,2025,3,2025-03-21T04:00:00Z,,2025-03-21T13:56:27Z,,0,0,0900006486a08a9d
FDA-2023-N-4225-0100,FDA,FDA-2023-N-4225,Request for Extension from Essential Minerals Association,Other,Request for Extension,2025-03-21T04:00:00Z,2025,3,2025-03-21T04:00:00Z,,2025-03-21T13:58:09Z,,0,0,0900006486a0bb00
FDA-2023-N-4225-0083,FDA,FDA-2023-N-4225,Memorandum re Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products (Proposed Rule),Other,Memorandum,2025-01-23T05:00:00Z,2025,1,2025-01-23T05:00:00Z,,2025-01-23T20:44:28Z,,0,0,09000064868f192c
FDA-2023-N-4225-0084,FDA,FDA-2023-N-4225,TAB A - Asbestos in Talc NPRM as Submitted to OMB,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:08Z,,0,0,09000064868f10ef
FDA-2023-N-4225-0087,FDA,FDA-2023-N-4225,TAB B - Asbestos in Talc PRIA Track Changes,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:28Z,,0,0,09000064868f10f2
FDA-2023-N-4225-0088,FDA,FDA-2023-N-4225,TAB C - Asbestos in Talc NPRM as Cleared by OMB,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:34Z,,0,0,09000064868f10f3
FDA-2023-N-4225-0086,FDA,FDA-2023-N-4225,TAB B - Asbestos in Talc NPRM Track Changes,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:23Z,,0,0,09000064868f10f1
FDA-2023-N-4225-0085,FDA,FDA-2023-N-4225,TAB A - Asbestos in Talc PRIA as Submitted to OMB,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:17Z,,0,0,09000064868f10f0
FDA-2023-N-4225-0089,FDA,FDA-2023-N-4225,TAB C - Asbestos in Talc PRIA as Cleared by OMB,Supporting & Related Material,Background Material,2025-01-23T05:00:00Z,2025,1,,,2025-01-23T20:46:41Z,,0,0,09000064868f10f4
FDA-2023-N-4225-0039,FDA,FDA-2023-N-4225,Reference 37 Rosner DG Nondetected The Politics of Measurem in Talc 1971 1976 AJPH Vol 2019,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:04Z,,0,0,090000648688cadb
FDA-2023-N-4225-0046,FDA,FDA-2023-N-4225,PRIA Footnote Reference 1 Updating Value per Statistical Life (VSL) Estimates for Inflation and Changes in Real Income,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:46Z,,0,0,090000648688cafa
FDA-2023-N-4225-0056,FDA,FDA-2023-N-4225,PRIA Reference 8 Passport Beauty and Personal Care in the US,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:50Z,,0,0,090000648688cb05
FDA-2023-N-4225-0002,FDA,FDA-2023-N-4225,List of references 12 11 2024,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:21Z,,0,0,090000648688caae
FDA-2023-N-4225-0028,FDA,FDA-2023-N-4225,Reference 26 - Lowers H -Tabulation of Asbestos Related Terminology 2002,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:58Z,,0,0,090000648688cad1
FDA-2023-N-4225-0029,FDA,FDA-2023-N-4225,Reference 27 - Campbell WJ Selected Silicate Minerals and Their Asbestiform Varieties US Bureau of Mines Information Circular 8751- 1977,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:04Z,,0,0,090000648688cad2
FDA-2023-N-4225-0043,FDA,FDA-2023-N-4225,Reference 41 USP-NF General Chapter Prospectus 1901_ Theory and Practices of Asbestos Detection in PHarmaceutical Talc 2021,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:29Z,,0,0,090000648688cadf
FDA-2023-N-4225-0059,FDA,FDA-2023-N-4225,PRIA Reference 11 Malignant Mesothelioma and Its Non-Asbestos Causes,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:06Z,,0,0,090000648688cb08
FDA-2023-N-4225-0018,FDA,FDA-2023-N-4225,Reference 16 Translocation of inhaled asbestos fibers from the lung to other tissues.pdf Suzuki Y 1991,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:54Z,,0,0,090000648688cac8
FDA-2023-N-4225-0052,FDA,FDA-2023-N-4225,PRIA Reference 4 Method J 4-1 Asbestiform Amphibole Minerals in Cosmetic Talc,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:26Z,,0,0,090000648688cb00
FDA-2023-N-4225-0054,FDA,FDA-2023-N-4225,PRIA Reference 6 White Paper IWGACP Scientific Opinions on Testing Methods for Asbestos in Cosmetic Products Containing Talc,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:39Z,,0,0,090000648688cb03
FDA-2023-N-4225-0004,FDA,FDA-2023-N-4225,Reference 2 Where is Asbestos Found ATSDR - Naturally Occurring Asbestos,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:33Z,,0,0,090000648688cab0
FDA-2023-N-4225-0019,FDA,FDA-2023-N-4225,Reference 17 Fitzgerald Comparing Historical and Recent Accelerated Concerns Regarding Asbestos in Talc 2021,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:00Z,,0,0,090000648688cac9
FDA-2023-N-4225-0021,FDA,FDA-2023-N-4225,Reference 19 FDA In Brief_ FDA Releases Final Report of Talc-containing cosmetic products tested for asbestos,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:12Z,,0,0,090000648688cacb
FDA-2023-N-4225-0051,FDA,FDA-2023-N-4225,PRIA Reference 3 Asbestos in Commercial Cosmetic Talcum Powder as a Cause of Mesothelioma in Women,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:21Z,,0,0,090000648688caff
FDA-2023-N-4225-0053,FDA,FDA-2023-N-4225,PRIA Reference 5 The U.S. Pharmacopeial Convention Revision Bulletin Talc,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:32Z,,0,0,090000648688cb01
FDA-2023-N-4225-0072,FDA,FDA-2023-N-4225,PRIA Reference 24 Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:17Z,,0,0,090000648688cb18
FDA-2023-N-4225-0074,FDA,FDA-2023-N-4225,PRIA Reference 26 Some Pitfalls of Practical Benefit-Cost Analys,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:28Z,,0,0,090000648688cb1a
FDA-2023-N-4225-0001,FDA,FDA-2023-N-4225,Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2024-12-27T05:00:00Z,2024,12,2024-12-27T05:00:00Z,2025-03-28T03:59:59Z,2025-03-29T01:00:19Z,2024-30544,0,0,090000648689150a
FDA-2023-N-4225-0006,FDA,FDA-2023-N-4225,Reference 4 Segrave Overview of the Geology of Cosmetic Talc Formation 2021,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:45Z,,0,0,090000648688cab2
FDA-2023-N-4225-0008,FDA,FDA-2023-N-4225,Reference 6 Toxicological Review of Libby Amphibole Asbestos EPA IRIS 2014,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:57Z,,0,0,090000648688cab4
FDA-2023-N-4225-0010,FDA,FDA-2023-N-4225,Reference 8 Toxicological Profile for Asbestos ATSDR 2001,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:08Z,,0,0,090000648688cab6
FDA-2023-N-4225-0023,FDA,FDA-2023-N-4225,Reference 21 Block Stimuli to the Revision Process Modernization of Asbestos Testing in Talc USP PF 40 4  2014,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:24Z,,0,0,090000648688caba
FDA-2023-N-4225-0017,FDA,FDA-2023-N-4225,Reference 15 Asbestos exposure and ovarian fiber burden.,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:49Z,,0,0,090000648688cac7
FDA-2023-N-4225-0041,FDA,FDA-2023-N-4225,Reference 39 USP CN Talc Detection of Asbestos in Pharmace Talc 1901 Theory and Practice of Asbestos Detection in Pharmace 2023..,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:18Z,,0,0,090000648688cadd
FDA-2023-N-4225-0049,FDA,FDA-2023-N-4225,PRIA Reference 1 National Toxicology Report on Carcinogens,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:10Z,,0,0,090000648688cafd
FDA-2023-N-4225-0057,FDA,FDA-2023-N-4225,PRIA Reference 9 Talc and Pyrophyllite Mineral Commodity Summary,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:54Z,,0,0,090000648688cb06
FDA-2023-N-4225-0061,FDA,FDA-2023-N-4225,PRIA Reference 13 Costs of Medical Care for Mesothelioma,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:17Z,,0,0,090000648688cb0d
FDA-2023-N-4225-0064,FDA,FDA-2023-N-4225,PRIA Reference 16 Cost of Care for the Initial Management of Ovarian Cancer,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:34Z,,0,0,090000648688cb10
FDA-2023-N-4225-0066,FDA,FDA-2023-N-4225,PRIA Reference 18 Guidelines for Regulatory Impact Analysis,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:45Z,,0,0,090000648688cb12
FDA-2023-N-4225-0070,FDA,FDA-2023-N-4225,PRIA Reference 22 Douching and Genital Talc Use Patterns of Use and Reliability of Self-reported Exposure,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:06Z,,0,0,090000648688cb16
FDA-2023-N-4225-0009,FDA,FDA-2023-N-4225,Reference 7 Filetti et al Update of in vitro  in vivo and ex vivo fluoro edenite effects of malignant mesothelioma 2020,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:02Z,,0,0,090000648688cab5
FDA-2023-N-4225-0015,FDA,FDA-2023-N-4225,Reference 13 IWGACP Appendices to White Paper January 13 2022,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:38Z,,0,0,090000648688cac5
FDA-2023-N-4225-0067,FDA,FDA-2023-N-4225,PRIA Reference 19 USP's Iterative Approach to Standards Development and the Emerging Standards,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:50Z,,0,0,090000648688cb13
FDA-2023-N-4225-0014,FDA,FDA-2023-N-4225,Reference 12 Asbestos hazards-and-safe-practice-for-clear-up-after-tsunami. 2006,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:33Z,,0,0,090000648688cac4
FDA-2023-N-4225-0033,FDA,FDA-2023-N-4225,Reference 31 - COPYRIGHT International Organization for Standardization ISO 22262-1-2012,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:27Z,,0,0,090000648688cad6
FDA-2023-N-4225-0036,FDA,FDA-2023-N-4225,Reference 34 - CIR Expert Panel Meeting March 18-19 2013 - Safety Assessment of Talc as Used in Cosmetics 2013,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:47Z,,0,0,090000648688cad8
FDA-2023-N-4225-0045,FDA,FDA-2023-N-4225,Talc PRIA Reference List,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:41Z,,0,0,090000648688caf9
FDA-2023-N-4225-0062,FDA,FDA-2023-N-4225,PRIA Reference 14 Lung Cancer Costs by Treatment Strategy and Phase of Care Among Patients Enrolled in Medicare,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:23Z,,0,0,090000648688cb0e
FDA-2023-N-4225-0068,FDA,FDA-2023-N-4225,PRIA Reference 20 Consolidated Financial Statements and Report of Independent Certified Public Accountants United States Pharmacopeial Convention and Subsidia,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:56Z,,0,0,090000648688cb14
FDA-2023-N-4225-0013,FDA,FDA-2023-N-4225,Reference 11 Asbestos - Overview _ Occupational Safety and Health Administration,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:27Z,,0,0,090000648688cac3
FDA-2023-N-4225-0022,FDA,FDA-2023-N-4225,Reference 20 Millette Procedure for the Analysis of Talc for Asbestos 2015,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:18Z,,0,0,090000648688cacc
FDA-2023-N-4225-0025,FDA,FDA-2023-N-4225,Reference 23 Peer review Report External Peer Review Comments and FDA Responses 2024,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:36Z,,0,0,090000648688cace
FDA-2023-N-4225-0031,FDA,FDA-2023-N-4225,Reference 29 Baumann Asbestos is not just asbestos_ an unrecognised health hazard 2013,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:16Z,,0,0,090000648688cad4
FDA-2023-N-4225-0037,FDA,FDA-2023-N-4225,Reference 35 Talc _ USP-NF Compendial Notices Intent to Revise Talc USP Monograph Asbestos Test Method 2020,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:52Z,,0,0,090000648688cad9
FDA-2023-N-4225-0044,FDA,FDA-2023-N-4225,Reference 42 Preliminary Regulatory Impact Analysis Asbestos in Talc PRIA,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:35Z,,0,0,090000648688caf8
FDA-2023-N-4225-0050,FDA,FDA-2023-N-4225,PRIA Reference 2 A Review of Human Carcinogens Part C Metals Arsenic Dusts and Fibres,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:16Z,,0,0,090000648688cafe
FDA-2023-N-4225-0058,FDA,FDA-2023-N-4225,PRIA Reference 10 Asbestos Contamination in Talc-Based Cosmetics An Invisible Cancer Risk,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:00Z,,0,0,090000648688cb07
FDA-2023-N-4225-0069,FDA,FDA-2023-N-4225,PRIA Reference 21 Sunscreen Drug Formulations for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:01Z,,0,0,090000648688cb15
FDA-2023-N-4225-0073,FDA,FDA-2023-N-4225,PRIA Reference 25 Perineal Use of Talc and Risk of Ovarian Cancer,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:23Z,,0,0,090000648688cb19
FDA-2023-N-4225-0003,FDA,FDA-2023-N-4225,Reference 1 Ultramafic hosted talc magnesite deposits 2006,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:27Z,,0,0,090000648688caaf
FDA-2023-N-4225-0011,FDA,FDA-2023-N-4225,Reference 9 IARC_Monograph_Asbestos.2012,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:14Z,,0,0,090000648688cab7
FDA-2023-N-4225-0034,FDA,FDA-2023-N-4225,Reference 32 - International Organization for Standardization ISO 10312-2019,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:33Z,,0,0,090000648688cabd
FDA-2023-N-4225-0027,FDA,FDA-2023-N-4225,Reference 25 Miller E. A review of the mesotheliogenic potency of cleavage fragments found in talc,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:52Z,,0,0,090000648688cad0
FDA-2023-N-4225-0030,FDA,FDA-2023-N-4225,Reference 28 Van Gosen - A USGS Study of Talc Deposits and Associated Amphibole ....Southern Death Valley Region Californina 2004,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:09Z,,0,0,090000648688cad3
FDA-2023-N-4225-0040,FDA,FDA-2023-N-4225,Reference 38 USP Talc Absence of Asbestos Test method Official May 1 2022,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:12Z,,0,0,090000648688cadc
FDA-2023-N-4225-0042,FDA,FDA-2023-N-4225,Reference 40 General Chapter Prospectus 901_ Detection of Asbestos in Pharmaceutical Talc 2021,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:23Z,,0,0,090000648688cade
FDA-2023-N-4225-0063,FDA,FDA-2023-N-4225,PRIA Reference 15 Treatment Survival and Costs of Laryngeal Cancer Care in the Elderly,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:28Z,,0,0,090000648688cb0f
FDA-2023-N-4225-0065,FDA,FDA-2023-N-4225,PRIA Reference 17 Recall Cost Cast Studies,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:39Z,,0,0,090000648688cb11
FDA-2023-N-4225-0071,FDA,FDA-2023-N-4225,PRIA Reference 23 The Environmental Injustice of Beauty Framing Chemical Exposures from Beauty Products as a Health Disparities Concern,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:56:12Z,,0,0,090000648688cb17
FDA-2023-N-4225-0024,FDA,FDA-2023-N-4225,Reference 22 Interagency Workgroup for Asbestos in Consumer Products IWGACP- White Paper 2022,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:29Z,,0,0,090000648688cacd
FDA-2023-N-4225-0026,FDA,FDA-2023-N-4225,Reference 24 Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:41Z,,0,0,090000648688cacf
FDA-2023-N-4225-0038,FDA,FDA-2023-N-4225,Reference 36 ISO IEC Guide 2 2004. Standardization and related activities General vocabulary 2004,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:59Z,,0,0,090000648688cada
FDA-2023-N-4225-0005,FDA,FDA-2023-N-4225,Reference 3 Virta Asbestos Geology Mineralogy Mining and Uses 2002,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:39Z,,0,0,090000648688cab1
FDA-2023-N-4225-0007,FDA,FDA-2023-N-4225,Reference 5 Asbestos. In Report on Carcinogens Fiftheenth Edition 2021,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:49:51Z,,0,0,090000648688cab3
FDA-2023-N-4225-0016,FDA,FDA-2023-N-4225,Reference 14 Ingested mineral fibers elimination in human urine Science 204 195-8 1979,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:44Z,,0,0,090000648688cac6
FDA-2023-N-4225-0020,FDA,FDA-2023-N-4225,Reference 18 FDA Talc Previous Activity,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:51:06Z,,0,0,090000648688caca
FDA-2023-N-4225-0035,FDA,FDA-2023-N-4225,Reference 33 IMA Amphibole Supergroup Mineral information data and localities,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:39Z,,0,0,090000648688cad7
FDA-2023-N-4225-0048,FDA,FDA-2023-N-4225,PRIA Footnote Reference 3 A Population-level Approach to Distributional Weighting,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:57Z,,0,0,090000648688cafc
FDA-2023-N-4225-0060,FDA,FDA-2023-N-4225,PRIA Reference 12 Under-Reporting of Adverse Drug Reactions A Systematic Review,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:55:12Z,,0,0,090000648688cb09
FDA-2023-N-4225-0012,FDA,FDA-2023-N-4225,Reference 10 Asbestos Selected Cancers NAS 2006,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:50:20Z,,0,0,090000648688cac2
FDA-2023-N-4225-0032,FDA,FDA-2023-N-4225,Reference 30 - National Institute for Occupational Safety and Health 2011,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:52:21Z,,0,0,090000648688cad5
FDA-2023-N-4225-0047,FDA,FDA-2023-N-4225,PRIA Footnote Reference 2 Circular A-4,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:53:52Z,,0,0,090000648688cafb
FDA-2023-N-4225-0055,FDA,FDA-2023-N-4225,PRIA Reference 7 Latent Period for Malignant Mesothelioma of Occupational Origin,Supporting & Related Material,Background Material,2024-12-27T05:00:00Z,2024,12,,,2024-12-30T02:54:44Z,,0,0,090000648688cb04